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Background: The stability of opioids and benzodiazepines was studied in patient urine samples stored at different
temperatures over 30 days.
Methods: Samples were prepared by solid phase extraction and quantified by liquid chromatography coupled to a
tandem triple quadrupole mass spectrometer.
Results: Sample storage conditions affected the stability of all drugs investigated. The concentrations of
hydromorphone and oxymorphone in urine samples from patients who had taken hydrocodone, morphine, and/or
oxycodone increased significantly over 30 days of storage.
Conclusions: These data suggest that results from long-term-stored urine samples with opioids and
benzodiazepines should be cautiously interpreted. This study indicates that the biotransformation of parent
drugs to metabolites still occurs during sample storage at ambient temperatures.
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In the USA, more attention has been placed during
the past decade on effective pain management due to
its contribution to the healing process and the im-
provement of the quality of patients’ lives. However,
according to the US Centers for Disease Control and
Prevention, pain medication prescription overdoses
have increased rapidly and are now at epidemic
levels (Centers for Disease Control and Prevention
2012). Recent studies have shown that physicians, in-
ternists, and family practitioners are more likely than
ever before to be supervising care of patients with
chronic pain who regularly have other comorbidities
and may be taking medications that could affect the
results of urine drug test (Couto et al. 2009). Couto
et al. found in their recent article that three quarters
of patients from nearly one million patient test* Correspondence: brent.dixon@pcls.com
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in any medium, provided the original work is psamples were not taking their medications according
to their physician’s prescription. Altogether, 38% of
patients did not have a detectable level of their pre-
scribed medication, while 27% had higher drug levels
and 15% had lower drug levels than expected (Couto
et al. 2009).
A review on the topic of drug instability by Peters in-
dicates that storage conditions are important factors
for data interpretation. Of particular note, compounds
that are structurally labile are most susceptible to deg-
radation (Peters 2007). Benzodiazepines and opioids
are among the most commonly prescribed drugs in
pain management therapy. Benzodiazepines are pre-
scribed particularly in anxiety-induced depression
cases, stress, panic, sleep disorders, and seizures, while
opioids have long been used to treat acute pain such as
postoperative pain and to alleviate the severe and dis-
abling pain of terminal conditions such as cancer.
However, these substances are regularly present in
emergency intoxication episodes and drugs-of-abuse
testing. They are also regularly responsible forn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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2004). Consequently, clinical and forensic laboratories
must be able to accurately screen, confirm, and
quantify benzodiazepines and opioids along with their
metabolites in biological samples.
The knowledge on drug concentration changes in
the sample and on the time of its storage period is
crucial particularly if there is a considerable time
interval between sample collection and toxicological
analysis (Skopp 2004). Samples are usually kept at
undefined storage conditions during transportation to
the laboratory, and toxicology laboratories are obliged
to keep biological samples for a certain period in
order to allow reanalysis if it is required by the prac-
titioner. Hence, the instability of the drugs (or benzo-
diazepines and opiates in this case) in different
biological samples (or urine in this case) is a problem
of data interpretation in analytical toxicology. Bio-
logical samples for toxicological analysis frequently
remain at room temperature for some hours during
transport, reception, and registration. Refrigeration of
samples at 4°C is common following drug screening
and analysis confirmation. For forensic purposes,
samples may be frozen for long time periods due to
legal constraints and subsequent retest. Some factors
such as storage time and temperature can influence
drug stability. It is one of the most important issues
challenging the interpretation of postmortem toxicol-
ogy results (Drummer 2007). A number of studies in
the literature are focused on the effects of sample
storage temperature and the formation of metabolites
(El Mahjoub and Staub 2000; Skopp et al. 2001a;
Skopp et al. 2001b; Klingmann et al. 2001; Clauwaert
et al. 2001), but these mainly report data from blood
and/or plasma samples.
Due to the high number of intoxications per year
with drugs and pharmaceuticals, fast drug screening
methods are necessary in clinical and forensic intoxi-
cation cases. Traditional methods usually include im-
munoassay testing and gas chromatography/mass
spectrometry (GC/MS) for confirmation. There are
intrinsic strengths and weaknesses associated with
these methods. Immunoassays are only available for a
small number of substance classes, and it suffers
from lack of specificity and sensitivity (Hammett-
Stabler and Cotten 2012). GC/MS requires a rigorous
sample preparation often involving derivatization of cer-
tain compounds and relatively long chromatographic runs
(Anizan et al. 2012). Liquid chromatography tandem mass
spectrometry (LC-MS/MS) has been increasingly used for
confirmation of drugs of abuse in various matrices (de
Castro et al. 2009a; de Castro et al. 2009b; Cheng et al.
2006; Mueller et al. 2005; de Jager and Bailey 2011). Multi-
plex triple quadrupole mass spectrometry has enabledsimultaneous detection of a drug and its fragment ions in
one single run.
The aim of the present study was to evaluate the
stability of opioids and benzodiazepines in patient
urine samples after different storage periods and tem-
peratures. A triple quadrupole mass spectrometer was
used to monitor the stability of six opioids and five
benzodiazepines in urine samples from four patients
with chronic pain, who have been under physicians’
supervision. Patient I was prescribed morphine and
oxycodone (Oxy Ir®), while patient II was prescribed
oxymorphone (Opana®) and oxycodone. Patient III
was prescribed hydrocodone and acetaminophen
(Lortab®), oxycodone and acetaminophen (Percocet®),
carisoprodol (Soma®), and diazepam (Valium®), and
patient IV was prescribed oxycodone and acetamino-
phen (Endocet®), carisoprodol (Soma®), and alprazolam
(Xanax®). The stability of parent compounds and cor-
responding metabolites was evaluated in urine sam-
ples stored at laboratory temperature or in the
refrigerator over 30 days.Materials and methods
Materials and reagents
Certified reference standards 6-acetylmorphine, mor-
phine, buprenorphine, hydromorphone, norbuprenor-
phine, hydrocodone, oxycodone, oxymorphone, alpha
hydroxy alprazolam, alprazolam, nordiazepam, oxaze-
pam, and temazepam were purchased from Cerilliant
(Round Rock, TX, USA). For quality control samples,
hydromorphone, oxycodone, oxymorphone, alprazolam,
oxazepam, and temazepam were purchased from Restek
(Bellefonte, PA, USA) while buprenorphine, alpha hy-
droxy alprazolam, and nordiazepam were purchased
from Grace (Deerfield, IL, USA). Norbuprenorphine, 6-
acetylmorphine, and alpha hydroxy alprazolam quality
control samples were different lot numbers from Cerilli-
ant. Deuterated internal standards oxycodone-d3,
buprenorphine-d4, hydromorphone-d3, norbuprenorphine-
d3, oxymorphone-d3, alpha hydroxy alprazolam-d5,
alprazolam-d5, oxazepam-d5, and temazepam-d5 were pur-
chased from Cerilliant. Each standard compound (1 mg/
mL) and internal standard (0.1 mg/mL) in methanol was
prepared in 30% methanol as working solutions. Aceto-
nitrile, methanol, and water were LC-MS grade and pur-
chased from J.T. Baker (Phillipsburg, NJ, USA). Reagent-
grade formic acid, phosphate buffer, and β-glucuronidase
enzyme were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Ammonium formate was purchased from
Hampton Research (Aliso Viejo, CA, USA). The 96-deep-
well plates for solid phase extraction (SPE; GV-65C 96-
deep-well) and sample collection were purchased from
Scienceware (Wayne, NJ, USA), while the Agilent 96-well
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used on the LC-MS autosampler.Sample collection and storage
Urine samples were obtained from four patients (I to IV)
with prescribed medications containing opioids and/or
benzodiazepines. Samples were received in our laboratory
within 24 h after collection and the analyses were per-
formed immediately. For compound stability investiga-
tion, urine samples were separated into two aliquots, in
polypropylene tubes, and stored at room temperature
(about 20°C) and at 4°C for 30 days. Urine samples were
prepared by SPE and analyzed by liquid chromatography
tandem mass spectrometry.
Sample preparation and SPE extraction
Samples were prepared using a Tecan Genesis RSP
100 Liquid Handler (Tecan Group Ltd., Männedorf,
Switzerland). For the standard calibration curve, 100 μL of
a 100-μg/mL stock solution (final concentration 5 μg/mL)
of internal standards was combined to 30% methanol in
water including the reference standard. The final volume
of each calibration standard level (1 to 6) was 2 mL. For
patient urine samples, 150 μL of urine samples, 38 μL of
internal standard mixed (250 ng/mL final concentrations),
300 μL of 0.1 M phosphate buffer pH 6.8, 130 μL of
β-glucuronidase enzyme, and 108 μL of water were
added in a 96-deep-well plate. An incubation at 47°C
for 2 h on a shaker followed. Following the enzymatic di-
gestion, 24 μL of 10% ammonium hydroxide was added
to each well and the plate was left at room temperature
for 20 min.
For SPE, the 96-deep-well SPE plate on a vacuum
manifold was preconditioned with methanol and
250 mM phosphate buffer pH 9. Samples (500 μL) were
then added, washed twice with 200 μL of 250 mM phos-
phate buffer pH 9, and eluted with three additions of
400 μL methanol. The eluate (1,200 μL) was evaporated
under nitrogen using a 96-well-plate evaporator system.
Samples were then reconstituted in 500 μL of 30%
methanol in water, incubated on a shaker for 10 min,
and centrifuged at 3,000 rpm for 10 min. The super-
natant (250 μL) was then transferred to the Agilent
96-well plate for LC-MS analysis.
LC-MS analysis
LC-MS analyses were performed on an Agilent 1290
Infinity LC coupled to an Agilent 6410 triple quadrupole
mass spectrometer (Agilent Technologies, Santa Clara,
CA, USA) with an electrospray ionization source. Chro-
matographic separation was carried out in a Poroshell
120SB-C18 column (2.1 × 100 mm, 2.7 μm; Agilent
Technologies, Santa Clara, CA, USA) with 99.9%water, 0.05% formic acid, and 0.05% ammonium formate
as mobile phase A, and 99.95% acetonitrile and 0.05%
formic acid as mobile phase B. The autosampler and the
column temperature were maintained at 6°C and 50°C re-
spectively. Gradient elution with mobile phase A and
mobile phase B at a flow rate of 0.7 mL/min was as fol-
lows: 5% to 50% B over 3 min, 50% to 95% B over
0.5 min, isocratic at 95% B for 0.6 min, 5% to 95% B over
0.1 min, and isocratic at 5% B over 0.7 min. Prior to the
next injection, the column was re-equilibrated at 5% B
over 1 min. A divert valve switched the LC flow ini-
tially to waste for 0.3 min, subsequently to the mass
spectrometer for 4.5 min, and then back to the waste
for the remaining chromatographic run.
Mass spectral data were obtained in positive electro-
spray mode, with the following parameters: nitrogen gas
temperature, 350°C; gas flow rate, 12 L/min; nebulizer
pressure, 45 psi; and capillary voltage, 4,000 V. Ion tran-
sitions for each analyte were optimized by flow injection
analysis of individual compounds (0.1 μg/mL in methanol)
using the Agilent MassHunter Optimizer software. Table 1
shows the transitions, the internal standard used for
each compound, the optimized fragmentor voltages for
the parent ion, as well as the collision energy for frag-
mentation of the product ions. Detection and quanti-
tation were performed by dynamic multiple reaction
monitoring (MRM) of at least two transitions for each
analyte and one transition for each internal standard.
The LC-MS analysis data were processed using Agilent
MassHunter Workstation.
Validation
Selectivity, sensitivity, linearity, intra-assay imprecision
and analytical recovery, extraction efficiency, matrix
effect, process efficiency, hydrolysis, and drug carry over
were evaluated. Potential endogenous interferences were
determined by the analysis of blank urine samples from
laboratory volunteers. Sensitivity of the method was ex-
amined by establishing the limit of quantitation (LOQ),
the half limit of quantitation (1/2 LOQ), and the intro-
duction of the initial calibration verification standards
(ICV) in the calibration curve standards. The accuracy
of each compound at each calibration level was between
80% and 120%. Linearity was determined using quadratic
regression with two replicates for each level. Six-level
calibration curves were used with the dilution pattern
1:2:2:2:2:4 for all compounds.
Extraction efficiency, matrix effect, and process effi-
ciency were calculated at three QC concentrations. A set
of samples containing the same amount of internal
standard and blank urine were spiked with different
amounts of analytes corresponding to levels 1, 3, and 5
of the calibration curve. The matrix effect was assessed
by comparing the peak areas of the analyte standards in
Table 1 Multiple reaction monitoring (MRM) transitions with optimized fragmentation voltage and collision energy
Compound RT (min) MW ISTD MRM transition (m/z) Fragmentor (V) CE (eV)
Opiates
6-Acetylmorphine 1.73 327.2 Oxycodone-d3 328.2 > 165.1 173 48
328.2 > 211.1 173 24
Buprenorphine 3.27 467.3 Buprenorphine-d4 468.3 > 55.1 208 44
468.3 > 396.2 208 40
Hydromorphone 0.92 285.2 Hydromorphone-d3 286.2 > 185.1 158 28
286.2 > 128.1 158 64
Norbuprenorphine 2.70 413.3 Norbuprenorphine-d3 414.3 > 152.1 235 100
414.3 > 165.1 235 104
Oxycodone 1.69 315.2 Oxycodone-d3 316.2 > 241.1 178 28
316.2 > 256.1 178 24
Oxymorphone 0.75 301.1 Oxymorphone-d3 302.1 > 284.2 179 16
302.1 > 227.1 179 28
Morphine 0.7 285.2 Morphine-d3 286.2 > 165.1 161 48
286.2 > 157.1 161 44
Hydrocodone 1.74 299.2 Hydrocodone-d3 300.2 > 199.1 167 28
300.2 > 171.1 167 40
Benzodiazepines
Alpha hydroxy alprazolam 3.35 324.1 Alpha hydroxy alprazolam-d5 325.1 > 216.1 105 40
325.1 > 279.1 105 40
Alprazolam 3.69 308.1 Alprazolam-d5 309.1 > 281.1 99 28
309.1 > 205.1 99 44
Nordiazepam 3.72 270.1 Temazepam-d5 271.1 > 140.1 161 24
271.1 > 208.1 161 28
Oxazepam 3.38 286.1 Oxazepam-d5 287.1 > 241.1 167 16
287.1 > 269.1 167 8
Temazepam 3.73 300.1 Temazepam-d5 301.1 > 255.1 198 20
301.1 > 177.1 198 40
Italicized transitions used for quantification. RT, retention time; MW, molecular weight; ISTD, internal standard; CE, collision energy.
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urine samples after extraction. The recovery and ion
suppression or enhancement associated with the blank
urine was evaluated by dividing the concentration of
standards from matrix-free with standards in blank urine
multiplied by 100.
Results and discussion
The combination of SPE followed by LC-MS analysis
is routinely used for metabolomics (Cheng and Mok
2004; Lu et al. 2008; Zhou et al. 2012). A similar pro-
cedure has been used to successfully quantify opioids
and benzodiazepines from patient urine samples,
using a triple quadrupole mass spectrometer. Triple
quadrupole tandem mass spectrometry provides
sensitive quantitation by acquiring the signalcorresponding to the highest response product ion
(quantifier) from the fragmentation of the compound
parent ion or precursor ion. The transition between
the parent ion and the product ion, known as MRM,
is subsequently used to acquire an additional signal
corresponding to the next highest product ion (quali-
fier) (Table 1) (Yost and Enke 1979; Yao et al. 2010).
This information may be considered as adequate for
confirmation and quantitation of analyte, particularly
if the ratio of signal between the two product ions is
consistent between the calibration standards and the
unknown samples. Dynamic MRM enables MRM ac-
quisitions of compounds during a retention time win-
dow corresponding to the elution time of each
compound, thus increasing the minimum dwell time
(Liu et al. 2011).
Figure 1 MRM and quantification of norbuprenorphine in urine extract. (A) MRM transition for the quantifier ion. (B) MRM transition for the
qualifier ion. (C) MRM transition for norbuprenorphine-d3 quantifier ion. (D) Six-duplicated-level calibration curve for norbuprenorphine. Concentration
range (20 to 1,280 ng/mL); R2≥ 0.995.
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Using six calibration levels, linear calibration curves
were obtained for all analytes with correlation (R2) equal
to or greater than 0.99 (Figure 1). The accuracy of all
analytes at all calibration levels was within 20% of the
nominal value. The method was also evaluated for the
potential presence of ion suppression or enhance-
ments due to matrix effects. The matrix effect was
found to be less than ±20% of the nominal values for
all compounds. This value is within the acceptable
range, as it has been found to vary between 4.5% and
39.5% in umbilical cord samples (de Castro et al. 2009a)
and ≤25% in urine samples (Cheng et al. 2006; de Jager
and Bailey 2011).
Compound stability
Urine samples from four patients under physicians’
supervision for pain management were analyzed over
30 days of storage. Table 2 shows patient medical pre-
scriptions, the expected compounds in the urine ana-
lyses, the detected compounds and metabolites, as well
the initial and final concentrations of the detected ana-
lytes after 30 days of storage. Analytes with initial con-
centrations higher than the higher level of quantitation
(HLOQ) were not selected for stability study. Successive
quantitation of drugs from patient urine samples wasmade in duplicate after 3, 8, 15, and 30 days of storage
at room temperature and at 4°C. The percentage of the
original amount of drug or metabolites remaining in
patient urine samples was calculated at day 30. After
30 days of investigation, no significant difference was de-
tected on the stability of opioids and benzodiazepines in
urine samples stored at 4°C and at room temperature
(Figure 2). The coefficient of variation of the remaining
drug stored at 4°C and at room temperature was 5% or
less. A comparison between the recoveries of blood
buprenorphine and morphine kept at 4°C and at 25°C
has previously been investigated (Hadidi and Oliver
1998). Morphine in blood was found to be reasonably
stable regardless of the storage time and temperatures
with a recovery ranging from 85% to 94% and from 76%
to 80% after 6 and 12 months of storage respectively.
Blood buprenorphine was found to be reasonably stable
at the storage temperatures with a recovery ranged from
77% to 101% and from 70% to 99% after 6 and 12 months
respectively (Hadidi and Oliver 1998). Anagnostis et al.
(2011) have recently investigated the stability of bupre-
norphine in solution stored at room temperature (20°C
to 25°C) and in the refrigerator (2.2°C to 7.8°C). Their
findings revealed that more than 95% of buprenorphine
in ethanolic solution is recovered after 30 days regard-
less of storage temperatures.
Table 2 Concentration of opioids and benzodiazepines in patient urine samples










I OxyIR® Morphine, oxycodone 6-Acetylmorphine 3 192 17 9 −
Hydromorphone 100 6,400 639 900 +
Morphine 100 6,400 (91,475) (146,125)
Oxycodone 50 3,200 (8,525) (12,346)
Oxymorphone 100 6,400 1,432 2,426 +
Nordiazepam 80 5,120 4,147 4,092 −
Oxazepam 80 5,120 4,830 4,684 −
80 5,120 3,630 2,469 −
II Opana®, oxycodone Oxymorphone, oxycodone Buprenorphine 10 640 23 24 +
Norbuprenorphine 20 1,280 94 86 −
Oxycodone 50 3,200 (13,076) (23,402)
Oxymorphone 100 6,400 (10,109) (15,006)
Alpha hydroxyl alprazolam 80 5,120 620 528 −





Hydrocodone 100 6,400 5,988 4,801 −
Hydromorphone 100 6,400 207 259 +
Oxycodone 50 3,200 3,197 2,941 −
Oxymorphone 100 6,400 365 774 +
Alpha hydroxyl alprazolam 80 5,120 133 57 −
Nordiazepam 80 5,120 1,733 1,533 −
Oxazepam 80 5,120 (6,604) (5,646)
Temazepam 80 5,120 3,891 2,953 −
IV Endocet®, Soma®, Xanax® Oxycodone, acetaminophen,
carisoprodo, alprazolam
Oxycodone 50 3,200 1,413 1,182 −
Oxymorphone 100 6,400 491 803 +
Alpha hydroxyl alprazolam 80 5,120 253 161 −
Alprazolam 80 5,120 1,003 890 −
Meprobamate 100 6,400 (14,016) (13,838)
LLOQ, lower level of quantification (level 1); HLOQ, higher level of quantification (level 6). aInitial concentration of the detected compounds; bconcentration of the
detected compounds after 30 days of storage at 4°C; cchange in the compound concentration after storage: increased (+), decreased (−).
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No significant difference was detected on the stability
of opioids in urine samples stored at 4°C and at
room temperature. The coefficient of variation of the
remaining drug stored at 4°C and at room tem-
perature was 5% or less for all compounds. Buprenor-
phine, norbuprenorphine, hydrocodone, and oxycodone
showed the best stability with 104%, 92%, 80%, and 84%
respectively of the concentration at day 1 after 30 days of
storage. 6-Acetylmorphine showed the least stability with
52%, while the concentration of hydromorphone and
oxymorphone increased drastically with 125% to 141%
and 164% to 212% respectively (Figure 3).
6-Acetylmorphine, a biologically specific indicator
marker of heroin, has a high occurrence in oral fluid fromusers of this drug, but due to its short half-life, its detection
in urine is limited (Allen 2011). Less than 50% of this me-
tabolite remained in the patient urine sample after 3 days
(Figure 3), and its concentration remained nearly constant
for the rest of the storage duration. After ingestion of her-
oin, it breaks down in minutes to 6-acetylmorphine and
then to morphine. This drug is not medically prescribed in
the USA, and it has been given schedule 1 status by the US
Drug Enforcement Administration. This drug has been
detected in patient I’s urine sample with prescribed medi-
cations containing morphine and oxycodone.
Buprenorphine and its metabolite norbuprenorphine
were both detected in patient II. The concentration of
the parent compound decreased over 8 days of storage,













Figure 2 Comparison of compound stability at 4°C and at room temperature (patient II). Stability of alpha hydroxy alprazolam (black circle),
alprazolam (black square), norbuprenorphine (black triangle), and buprenorphine (black diamond) in urine samples stored at 4°C (C, solid marker)
and at room temperature (RT, open marker). Drug recovery after 30 days of storage, alpha hydroxy alprazolam (85% at 4°C, 89% at RT); alprazolam
(95% at 4°C, 90% at RT); norbuprenorphine (92% at 4°C, 95% at RT); and buprenorphine (104% at 4°C, 85% at RT).
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norphine has recently been investigated in whole blood
samples from suspected drug users (Selden et al. 2011).
This investigation revealed that buprenorphine and nor-
buprenorphine showed some degradation when stored at
4°C for 3 weeks, and in many cases, the concentrations
of buprenorphine were very low compared to norbupre-
norphine. These findings support the evidence that
buprenorphine may be converted to norbuprenorphine
in whole blood sample at 4°C, but this conversion in
urine sample has not previously been demonstrated. In
the present study, the increase in the concentration of
norbuprenorphine is probably due to degradation of
buprenorphine.
Hydromorphone and oxymorphone were detected in
patients I, III, and IV who were prescribed medications
containing morphine and/or oxycodone. Evidence for
morphine metabolism to hydromorphone in pain pa-
tients chronically treated with morphine has extensively
been confirmed (Cone et al. 2006; Hughes et al. 2012).
Likewise, the metabolism of oxycodone to oxymorphone
in pain patients has also been demonstrated (Yee et al.
2012). However, the occurrence of this transformation in
stored urine samples has not been previously demon-
strated. After ingestion, morphine is metabolized in the
liver into morphine-3-glucuronide and morphine-6-
glucuronide (Kilpatrick and Smith 2005). It may also be
metabolized into normorphine, codeine, and hydromor-
phone, but the metabolism rate is determined by gender,
age, diet, genetic makeup, disease state, and the use of
other medications. In humans, oxycodone is primarily
metabolized in the liver to α and β oxycodol and oxy-
morphone (Moore et al. 2003). Some patients are fast
metabolizers of oxycodone, resulting in reduced anal-
gesic effect but increased adverse effects, while othersare slow metabolizers resulting in increased toxicity
without improved analgesia (Gasche et al. 2004). The
concentrations of the metabolites hydromorphone and
oxymorphone in urine samples after 30 days of storage
were very high compared to the initial concentration at
day 1 and independently to patients. This trend once more
supports the evidence that parent compounds may be
converted into corresponding metabolites in urine sam-
ples stored at 4°C. The metabolite concentration levels de-
pend on the concentration of the parent compounds.
These two metabolites can still be analyzed in patient
urine samples stored at 4°C for 30 days, when patients
have been prescribed medications containing the main
compounds.
Stability of benzodiazepines
Unlike the variation in the concentrations of opioids in-
vestigated, the concentrations of all benzodiazepines de-
creased over 30 days of storage at 4°C. Alprazolam,
nordiazepam, and oxazepam showed the best stability
with 95%, 90% to 98%, and 97% of the original concen-
tration at day 1 respectively, while alpha hydroxy al-
prazolam (43% to 85%) and temazepam (68% to 78%)
showed more degradation (Figure 3).
In humans, alprazolam is extensively metabolized to
alpha hydroxy alprazolam and 4-hydroxy alprazolam,
whose plasma concentrations relative to unchanged al-
prazolam concentration are less than 4% (Smith et al.
1984). The stability of alprazolam is attributed to the
presence of the triazole ring in its structure which makes
the compound more resistant to hydrolysis. In a recent
study on the stability of benzodiazepines in postmortem
samples, estazolam whose structure is similar to alprazo-
lam was the most stable in unpreserved blood samples
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Figure 3 Change in urine opioid and benzodiazepine recovery with time. Change in detected compounds from patient I (A), patient II (B),
patient III (C), and patient IV (D).
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prazolam and alpha hydroxy alprazolam were detected
in patients II and IV, but only patient IV has been pre-
scribed medications containing alprazolam.
The main active metabolite of diazepam is nordiaze-
pam and the minor active metabolites are oxazepam and
temazepam (Riss et al. 2008). The half-life of diazepam
is about 1 to 3 days and 2 to 7 days for nordiazepam.
The elimination half-life of diazepam and nordiazepam
increases considerably in the elderly, which may result
in the prolonged action and accumulation of the drug
during repeated administration (Vozeh 1981). Nordiaze-
pam, oxazepam, and temazepam were detected in
patients I and III, but only patient III was under pre-
scription of medications containing diazepam, the parent
compound. Nordiazepam and oxazepam were the most
stable compared to temazepam. Atanasov et al. recently
investigated the stability of diazepam in blood samples
at different storage conditions (Atanasov et al. 2012).
The authors showed that the concentration of diazepam
decreased by 30% after storage for 4 weeks at 4°C. How-
ever, diazepam and chlordiazepoxide are benzodiazepines
with long-acting active metabolites like nordiazepam. We
could also observe an increase in the concentration of
nordiazepam (patients I and III) after 2 weeks of storage at
4°C, thus suggesting diazepam degradation into nordiaze-
pam (Figure 3). The data obtained from this study sug-
gested that opioid and benzodiazepine degradation with
consequent metabolites may occur by chemical break-
down during storage. In postmortem samples, it has been
suggested that decomposition may occur due to microor-
ganisms’ activity (Melo et al. 2012; Levine et al. 1983).
Conclusions
This work implies that some patients do not take their
medications according to their physician’s prescription
or take illicit drugs in addition to their prescriptions.
When interpreting toxicological results related to pos-
sible opioid or benzodiazepine exposure, it is important
to consider that the presence of their metabolites in urine
samples can be due to patient biotransformation of the
drug (in vivo), but also due to their decomposition during
storage (in vitro). Opioid and benzodiazepine concentra-
tions in urine samples can change due to degradation
during sample storage. This study revealed that opioid
and benzodiazepine degradation increased with storage
time. The change in concentration of metabolites after
sample storage suggests that the biotransformation of
parent drugs to metabolites still occurs during storage at
positive temperatures. Quantitative results from long-
term-stored urine samples with opioids or benzodiaze-
pines should be interpreted cautiously. Ongoing monitor-
ing of these patients will help the laboratory and clinician
draw conclusions on patient adherence to theirprescription regimen. In efforts to enable accurate inter-
pretation of the toxicological results, it is important to
know the stability of the drugs at several storage condi-
tions and in different matrices. This study demonstrates
the need for more detailed studies of in vitro changes of
analytes in biological samples and in urine samples par-
ticularly. By considering other work related to this topic,
and by conducting more research aimed at particular
storage conditions, degradation models may be applied.Findings
The purpose of this study was to investigate the stability
of opioid and benzodiazepine drugs and metabolites in
stored urine specimens. This is an area of interest for
clinical and forensic toxicology applications. The data
was collected under validated methodologies with quality
control samples run with each batch. The results demon-
strated that sample collection and storage conditions are
important considerations in the context of drug testing.
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